- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia , a leading clinical hepatologist about ammonia-driven diseases, and a caregiver...
CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 44 th Annual...
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients   — KRRO-110 did not reach projected...
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio today and set a price target of $180.00. The company’s shares closed yesterday at $45.72.Elevate Your Investing Strategy: Take...
CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific...
—  Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 —  Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple...